← Leaderboards
Vicente Planelles
Utah State Higher Education System--University Of Utah
$15,017,567
Attributed
$21,378,835
Total exposure
17
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,378,835 · 17
By mechanism
R01$13,509,498 · 5
R21$2,537,013 · 6
T32$1,859,565 · 1
U19$1,826,934 · 2
R33$1,077,023 · 1
R56$336,375 · 1
Top collaborators
- Sumit K Chanda5 shared
- Mayte Coiras5 shared
- Matthew A Mulvey5 shared
- Matthew Thomas Rondina4 shared
- Andrew Scott Weyrich4 shared
- Edward Barker2 shared
- Louis R Barrows2 shared
- Heidi L Schubert2 shared
Most similar at Utah State Higher Education System--University Of Utah
Same institution · by research overlap
- Mayte Coiras$1,144,469
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHiv-1ViralIn VitroInfectionPathway InteractionsIn VivoT-LymphocyteCd4 Positive T LymphocytesMediatingGene ExpressionCytokineCell TypeSignal TransductionT Memory CellBaseMacrophageSignal PathwayAntiretroviral TherapyPublic Health RelevanceReactivation From LatencyPharmaceutical PreparationsImmunePathogenesis
Grant awards (60)
Training Program in Microbial Pathogenesis$464,573
T32 · FY2025 · AI
Training Program in Microbial Pathogenesis$345,063
T32 · FY2024 · AI
Control of HIV-1 Transcription by CPSF6 and PP2A$192,500
R21 · FY2024 · AI · contact PI
Tyrosine Kinase inhibition: The New Front in HIV Cure Efforts$442,650
R01 · FY2023 · AI · contact PI
Training Program in Microbial Pathogenesis$258,611
T32 · FY2023 · AI
Control of HIV-1 Transcription by CPSF6 and PP2A$231,000
R21 · FY2023 · AI · contact PI
Tyrosine Kinase inhibition: The New Front in HIV Cure Efforts$410,850
R01 · FY2022 · AI · contact PI
Training Program in Microbial Pathogenesis$387,040
T32 · FY2022 · AI
Tyrosine Kinase inhibition: The New Front in HIV Cure Efforts$454,331
R01 · FY2021 · AI · contact PI
Training Program in Microbial Pathogenesis$404,278
T32 · FY2021 · AI
Development of SMAC mimetics as latency-reversing agents$664,048
R01 · FY2020 · AI
Tyrosine Kinase inhibition: The New Front in HIV Cure Efforts$471,902
R01 · FY2020 · AI · contact PI
Preclinical Development of Ingenol and HDACi Toward HIV Eradication$350,542
R33 · FY2020 · AI · contact PI
Development of SMAC mimetics as latency-reversing agents$664,048
R01 · FY2019 · AI
Tyrosine Kinase inhibition: The New Front in HIV Cure Efforts$509,204
R01 · FY2019 · AI · contact PI
Preclinical Development of Ingenol and HDACi Toward HIV Eradication$350,542
R33 · FY2019 · AI · contact PI
Development of SMAC mimetics as latency-reversing agents$664,048
R01 · FY2018 · AI
Preclinical Development of Ingenol and HDACi Toward HIV Eradication$375,939
R33 · FY2018 · AI · contact PI
The Effects of ART on Platelets and HIV-Associated Thrombosis$743,914
R01 · FY2017 · HL
Development of SMAC mimetics as latency-reversing agents$663,969
R01 · FY2017 · AI
Discovery and Characterization of Latency-Reversing Compounds$189,479
R21 · FY2017 · AI
CRISPR/Cas9 technology toward understanding HIV latency in primary cells$189,375
R21 · FY2017 · AI · contact PI
Preclinical Development of Ingenol and HDACi Toward HIV Eradication$186,250
R21 · FY2017 · AI · contact PI
The Effects of ART on Platelets and HIV-Associated Thrombosis$743,914
R01 · FY2016 · HL
Development of SMAC mimetics as latency-reversing agents$710,559
R01 · FY2016 · AI
Discovery and Characterization of Latency-Reversing Compounds$226,563
R21 · FY2016 · AI
CRISPR/Cas9 technology toward understanding HIV latency in primary cells$226,500
R21 · FY2016 · AI · contact PI
Preclinical Development of Ingenol and HDACi Toward HIV Eradication$223,500
R21 · FY2016 · AI · contact PI
The Effects of ART on Platelets and HIV-Associated Thrombosis$732,755
R01 · FY2015 · HL
Activity of novel drug candidates in primary cell models of HIV latency$302,821
U19 · FY2015 · AI · contact PI
The Effects of ART on Platelets and HIV-Associated Thrombosis$743,914
R01 · FY2014 · HL
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells$368,775
R01 · FY2014 · AI · contact PI
Activity of novel drug candidates in primary cell models of HIV latency$259,608
U19 · FY2014 · AI · contact PI
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells$345,403
R01 · FY2013 · AI · contact PI
Activity of novel drug candidates in primary cell models of HIV latency$302,287
U19 · FY2013 · AI · contact PI
Using NK Cells to eliminate the latent HIV reservoir$226,462
U19 · FY2013 · AI · contact PI
Activity of novel drug candidates in primary cell models of HIV latency$409,729
U19 · FY2012 · AI · contact PI
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells$370,013
R01 · FY2012 · AI · contact PI
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells$370,838
R01 · FY2011 · AI · contact PI
Activity of novel drug candidates in primary cell models of HIV latency$326,027
U19 · FY2011 · AI · contact PI
An Ex Vivo Model of HIV-1 Latency and Reactivation using Primary Memory Cells$376,250
R01 · FY2010 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$317,211
R01 · FY2010 · AI · contact PI
Modulation of surface markers by HIV-1 Vpu/Vpr and sensitivity to NK cell lysis$187,813
R21 · FY2010 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$142,614
R01 · FY2010 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$320,414
R01 · FY2009 · AI · contact PI
Modulation of surface markers by HIV-1 Vpu/Vpr and sensitivity to NK cell lysis$234,970
R21 · FY2009 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$320,414
R01 · FY2008 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$326,620
R01 · FY2007 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$168,188
R01 · FY2006 · AI · contact PI
Induction of Apoptosis by HIV-1 vpr$336,375
R56 · FY2005 · AI
INDUCTION OF APOPTOSIS BY HIV-1 VPR$299,000
R01 · FY2004 · AI
INDUCTION OF APOPTOSIS BY HIV-1 VPR$299,084
R01 · FY2003 · AI
Activation of a DNA damage pathway by HIV-1 vpr$224,250
R21 · FY2003 · AI
INDUCTION OF APOPTOSIS BY HIV-1 VPR$255,000
R01 · FY2002 · AI
Activation of a DNA damage pathway by HIV-1 vpr$224,813
R21 · FY2002 · AI
INDUCTION OF APOPTOSIS BY HIV-1 VPR$213,730
R01 · FY2001 · AI
PP2A AND THE INDUCTION OF G2 ARREST BY HIV1 VPR$118,492
R29 · FY2001 · AI
INDUCTION OF APOPTOSIS BY HIV-1 VPR$94,688
R01 · FY2001 · AI
INDUCTION OF APOPTOSIS BY HIV-1 VPR$301,150
R01 · FY2000 · AI
PP2A AND THE INDUCTION OF G2 ARREST BY HIV1 VPR$113,935
R29 · FY2000 · AI